Chemical subgroup
L01XX – Andere antineoplastische Mittel
16Decisions
27Patient groups
Added benefit by patient group
- Considerable4
- Minor4
- Non-quantifiable2
- Not proven17
Decisions, newest first
- 2026-04-02OgsiveoNirogacestatMinor
- 2025-09-18WeliregBelzutifanNot proven
- 2025-09-18WeliregBelzutifanMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2024-05-16KimmtrakTebentafuspConsiderable
- 2023-08-03LumykrasSotorasibNon-quantifiable: 1 of 3 patient groupsNot proven: 2 of 3 patient groups
- 2023-03-16NexpovioSelinexorNot proven
- 2023-03-16NexpovioSelinexorNot proven
- 2022-08-04LumykrasSotorasibNot proven
- 2021-12-02VenclyxtoVenetoclaxConsiderable
- 2021-12-02ElzonrisTagraxofuspNon-quantifiable
- 2020-10-15VenclyxtoVenetoclaxNot proven: 3 of 3 patient groups
- 2019-05-16VenclyxtoVenetoclaxNot proven: 2 of 2 patient groups
- 2019-05-16VenclyxtoVenetoclaxMinor: 1 of 3 patient groupsNot proven: 2 of 3 patient groups
- 2016-12-01HalavenEribulinConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2015-01-22HalavenEribulinConsiderable: 1 of 3 patient groupsNot proven: 2 of 3 patient groups
- 2013-08-15ZaltrapAfliberceptMinor
Data status: 2026-10-29